Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)
Pediatric Blood & Cancer2010Vol. 55(1), pp. 26–34
Citations Over TimeTop 1% of 2010 papers
John M. Maris, Christopher L. Morton, Richard Görlick, E. Anders Kolb, Richard B. Lock, Hernán Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, Jianrong Wu, Malcolm A. Smith, Peter J. Houghton
Abstract
The in vivo activity observed against the neuroblastoma panel far exceeds that observed for standard agents evaluated against the panel by the PPTP. High levels of in vivo activity were also observed against the ALL xenograft panel. These data support expedited clinical development of MLN8237 in childhood cancer.
Related Papers
- → Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma(2006)46 cited
- → PRMT1 is an important factor for medulloblastoma cell proliferation and survival(2022)7 cited
- → Is adult medulloblastoma merely the counterpart of pediatric medulloblastoma?(2020)1 cited
- → Atypical Cases of Osteosarcoma.(1991)
- The expression and significance of Pgp in wilms' tumor and medulloblastoma in children(1999)